Publication | Closed Access

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial

Ovarian Cancer TrialOncologyMedicineGynecologyTumor TargetingAnti-cancer AgentCarboplatin-paclitaxel CombinationCancer TreatmentPharmacologyHypersensitivity ReactionsOvarian Cancer